Last reviewed · How we verify
CC-42344
CC-42344 is a small molecule inhibitor of the SARS-CoV-2 main protease.
CC-42344 is a small molecule inhibitor of the SARS-CoV-2 main protease. Used for Treatment of COVID-19.
At a glance
| Generic name | CC-42344 |
|---|---|
| Also known as | Active |
| Sponsor | Cocrystal Pharma, Inc. |
| Drug class | SARS-CoV-2 main protease inhibitor |
| Target | SARS-CoV-2 main protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
CC-42344 works by binding to the SARS-CoV-2 main protease, which is essential for the viral replication. This binding prevents the protease from processing the viral polyprotein, ultimately inhibiting the replication of the virus. As a result, CC-42344 has the potential to treat COVID-19.
Approved indications
- Treatment of COVID-19
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- CC-42344 Safety Study in Healthy Participants (PHASE1)
- Influenza Viral Challenge Study of CC-42344 in Healthy Participants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CC-42344 CI brief — competitive landscape report
- CC-42344 updates RSS · CI watch RSS
- Cocrystal Pharma, Inc. portfolio CI